The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

Anthony G Marson; Girvan Burnside; Richard Appleton; Dave Smith; John Paul Leach; Graeme J. Sills; Catrin Tudur Smith; Catrin Plumpton; Dyfrig Hughes; Paula Williamson; Gus A. Baker; Silviya Balabanova; Claire Taylor; Richard Brown; D Hindley; Stephen Howell; Melissa Maguire; Rajiv Mohanraj; Phil E M Smith; Karen Lanyon; Mark Manford; Manali Chitre; Alasdair Parker; Nina Swiderska; Richard Appleton; James Pauling; Adrian Hughes; Rajat Das Gupta; Sadia Hanif; Mostafa Awadh; Sharmini Ragunathan; Nicola Cable; Paul Cooper; Daniel Hindley; Karl Rakshi; Sophie Molloy; Markus Reuber; Kunle Ayonrinde; Martin Wilson; Satyanarayana Saladi; John Gibb; Lesley-Ann Funston; Damhait Cassidy; Jonathan Boyd; Mal Ratnayaka; Hani Faza; Martin Sadler; Hassan Al-Moasseb; Clare Galtrey; Damien Wren; Anas Olabi; Geraint Fuller; Muhammed Khan; Chetana Kallappa; Ravi Chinthapalli; Baba Aji; Rhys Davies; Kathryn A. Foster; Nikolas Hitiris; Melissa Maguire; Nahin Hussain; Simon Dowson; Julie Ellison; Basil Sharrack; Vandna Gandhi; Robert Powell; Phil Tittensor; Beatrice A. Summers; Sastry Shashikiran; Penelope J Dison; Shanika Samarasekera; Doug McCorry; Kathleen M. White; Kannan Nithi; Martin Richardson; Richard Brown; Rupert Page; David Deekollu; Sean Slaght; Stephen Warriner; Mansoor Ahmed; Abhijit Chaudhuri; Gabriel Chow; Javier Carod Artal; Danute Kucinskiene; Harish Sreenivasa; Singara Velmurugan; Christos Zipitis; Brendan McLean; Vaithianathar Lal; Angelous Gregoriou; Paul Maddison; Trevor Pickersgill; Joseph Anderson; Charlotte Lawthom; Stephen Howell; Gabriel Whitlingum; Wojtek Rakowicz; Lucy Kinton; Alisa McLellan

doi:10.1016/s0140-6736(21)00246-4

April 1, 2021The LancetOpen Access

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

National Institute for Health Research Health Technology Assessment Programme.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Marson et al. (2021) studied this question.

synapsesocial.com/papers/69dd5f81ae7c4d5b29100e0b https://doi.org/10.1016/s0140-6736(21)00246-4

View Full Paper

Ask AI

Bookmark

Share

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

No abstract yet

Ask about this paper

Abstract

Discussion

Cite This Study

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

No abstract yet

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading